Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9023391 | DEXCEL PHARMA | Stable benzimidazole formulation |
Aug, 2025
(2 years from now) | |
US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) |
Market Authorisation Date: 04 December, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE;ORAL
8
United States
4
Israel
3
European Union
2
Australia
1
Germany
1
Spain
1
Austria
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic